Compare Johnson & Johnson (JNJ) vs Matson Inc (MATX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Matson Inc — how do they compare? Johnson & Johnson trades at $261.24 (market cap $618.09B), while Matson Inc trades at $226.21 (market cap $6.81B). The key difference: Johnson & Johnson is far larger — about 90.8× Matson Inc's market cap, and Johnson & Johnson pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Matson Inc for 23 Days on average.
| JNJ | MATX | |
|---|---|---|
Market Cap | $618.09B | $6.81B |
Volume | 6,050,983 | 255,080 |
Sector | Health | Industrials |
52-Week High | $278.43 | $238.60 |
52-Week Low | $186.00 | $88.05 |
Typical Hold Time | 129 Days | 23 Days |
Enterprise Value | $646.37B | $7.41B |
Dividend Yield | 2.09% | 0.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
Matson (MATX) trades at $222.92, down 0.83% on the day, with technical indicators showing a neutral to bearish short-term bias. The company demonstrates strong fundamental performance with consistent earnings beats, including Q2 2026 EPS of $4.27 versus $3.79 expected, and maintains healthy profitability with a 13.41% net income margin. Recent news highlights institutional buying interest and positive analyst sentiment toward the transportation services sector.
MATX presents a compelling investment case with solid earnings growth, attractive valuation metrics (P/E of 15.37), and strong analyst support (66.7% buy ratings). Key risks include freight market volatility and competitive pressures, but the company's raised full-year outlook and dividend payments provide stability. The stock offers potential upside with Wall Street analysts projecting 27.3% price target upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Matson Inc
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →
